54450-84-9

Basic information

• Product Name: CYCLOBUTANE-1,1-DICARBOXYLIC ACID ETHYL ESTER
• Synonyms: CYCLOBUTANE-1,1-DICARBOXYLIC ACID ETHYL ESTER;1-(ethoxycarbonyl)cyclobutane-1-carboxylic acid;1,1-Cyclobutanedicarboxylic acid, 1-ethyl ester;Monoethyl 1,1-cyclobutanedicarboxylate
• CAS NO: 54450-84-9
• Molecular Formula: C₈H₁₂O₄
• Molecular Weight: 172.179
• Mol File: 54450-84-9.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 276.627°C at 760 mmHg
• Flash Point: >110℃
• Appearance: /
• Density: 1.117 g/mL at 25 °C
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: n20/D1.451
• PKA: 3.00±0.20(Predicted)
• CAS DataBase Reference: CYCLOBUTANE-1,1-DICARBOXYLIC ACID ETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: CYCLOBUTANE-1,1-DICARBOXYLIC ACID ETHYL ESTER(54450-84-9)
• EPA Substance Registry System: CYCLOBUTANE-1,1-DICARBOXYLIC ACID ETHYL ESTER(54450-84-9)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22-36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 54450-84-9(Hazardous Substances Data)

Usage

General Description

Cyclobutane-1,1-dicarboxylic acid ethyl ester is a chemical compound categorized under the esters class with a molecular formula of C8H12O4. CYCLOBUTANE-1,1-DICARBOXYLIC ACID ETHYL ESTER involves an ethoxy group attached to the carbon atom of a four-membered cyclobutane ring, in which two carbons of the same ring are further substituted with carboxy groups. It appears as a clear, colorless liquid at room temperature. Details including its detailed chemical structure, physical properties, reactivity, and potential uses are usually determined through specific scientific evaluation and analysis. The compound, like others in its class, may have potential applications in various industrial processes or chemical syntheses.

InChI:InChI=1/C8H12O4/c1-2-12-7(11)8(6(9)10)4-3-5-8/h2-5H2,1H3,(H,9,10)

Upstream product

• 105-53-3 diethyl malonate 
• 3779-29-1 diethyl cyclobutane-1,1-dicarboxylate 
• 3721-95-7 Cyclobutanecarboxylic acid 
• 541-41-3 chloroformic acid ethyl ester 

Downstream Products

• 1075-81-6 Cyclobutan-1,1-dicarbonsaeure-ethylester-chlorid 
• 1040683-08-6 ethyl 1-(trifluoromethyl)cyclobutane-1-carboxylate 
• 1447941-04-9 O'1,O₁-([1,1'-biphenyl]-4,4'-diylbis(2-oxoethane-2,1-diyl)) 1-diethyl bis(cyclobutane-1,1-dicarboxylate) 
• 163554-55-0 tert-butyl (1-formylcyclobutyl)carbamate 
• 219322-95-9 1-<2-bromo-1,1-(ethylenedioxy)ethyl>-carbamoyl-1-cyclobutane carboxamide 
• 219322-94-8 1-<1,1-(ethylenedioxy)ethyl>-carbamoyl-1-cyclobutane carboxamide 
• 219322-96-0 5,8-dioxo-6-<1(R)-phenylethyl>-6-azaspiro<3.4>octane 8-ethylene acetal 
• 219322-91-5 ethyl 1-carbamoyl-1-cyclobutane carboxylate 
• 219322-92-6 1-carbamoyl-1-cyclobutane carboxylic acid 
• 219322-93-7 1-acetyl-1-carbamoyl-1-cyclobutane 

Relevant articles and documents

CONJUGATED CHEMICAL INDUCERS OF DEGRADATION AND METHODS OF USE

The subject matter described herein is directed to antibody-CIDE conjugates (Ab-CIDEs), to pharmaceutical compositions containing them, and to their use in treating diseases and conditions where targeted protein degradation is beneficial.

Discovery of potent c-MET inhibitors with new scaffold having different quinazoline, pyridine and tetrahydro-pyridothienopyrimidine headgroups

Cellular mesenchymal-epithelial transition factor (c-MET) is closely linked to human malignancies, which makes it an important target for treatment of cancer. In this study, a series of 3-methoxy-N-phenylbenzamide derivatives, N-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl) benzamide derivatives and N1-(3-fluoro-4-methoxyphenyl)-N3-(4-fluorophenyl) malonamide derivatives were designed and synthesized, some of them were identified as c-MET inhibitors. Among these compounds with new scaffolds having different quinazoline, pyridine and tetrahydro-pyridothienopyrimidine head groups, compound 11c, 11i, 13b, 13h exhibited both potent inhibitory activities against c-MET and high anticancer activity against tested cancer cell lines in vitro. In addition, kinase selectivity assay further demonstrated that both 13b and 13h are potent and selective c-MET inhibitors. Molecular docking supported that they bound well to c-MET and VEGFR2, which demonstrates that they are potential c-MET RTK inhibitors for cancer therapy.

Ruthenium-catalyzed asymmetric hydrogenation of 3-oxoglutaric acid derivatives: A study of unconventional solvent and substituent effects

A series of 3-oxoglutaric acid derivatives have been hydrogenated in different solvents in the presence of [RuCl(benzene)(S)-SunPhos]Cl (SunPhos=(2,2,2′,2′-tetramethyl-[4,4′-bibenzo[d][1,3]dioxole] -5,5′-diyl)bis(diphenylphosphine)). Unlike simple β-keto acid derivatives, these advanced analogues can be readily hydrogenated in uncommon solvents such as THF, CH2Cl2, acetone, and dioxane with high enantioselectivities. Two possible catalytic cycles have been proposed to explain the different reactivities of these 1,3,5-tricarbonyl substrates in the tested solvents. The C-2 and C-4 substituents had notable but irregular influence on the reactivity and enantioselectivity of the reactions. More pronounced solvent effects were observed: the ee values increased from around 20 % in EtOH or THF to 90 % in acetone. Inversion of the product configuration was observed when the solvent was changed from EtOH to THF or acetone, and a mixed solvent system can lead to better enantioselectivity than a single solvent. Pronounced solvent effects: 3-Oxoglutaric acid derivatives have been hydrogenated in various solvents with high enantioselectivities (see scheme). Inversions of the product configuration were observed when the solvent was changed. Mixed solvent systems can give better enantioselectivities than a single solvent.